Lars Rasmussen, BSc Engineering and MBA, was born on 31 March 1959 and is a Danish citizen. He was nominated for election to Lundbeck's Board of Directors at the 2013 annual general meeting. He chairs Lundbeck’s Remuneration and Scientific Committees, and is member of Lundbeck's Audit Committee.
Lars Rasmussen has considerable management experience in global med-tech. Lars Rasmussen was appointed as CEO of Coloplast A/S in 2008 and has been member of the company's executive management since 2001. In this period, he has been responsible for various functions in the group, including global sales, innovation and production. He has performed these duties from both Denmark and the USA.
Lars Rasmussen's special qualifications for serving on Lundbeck's Board of Directors include his top management experience and knowledge of efficiency improvements and internationalisation.
Lars Rasmussen is member of the Board of Directors of William Demant Holding A/S.
Lene Skole, BCom Finance, was born on 28 April 1959 and is a Danish citizen. She was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. She is member of Lundbeck's Remuneration and Scientific Committees.
Lene Skole is CEO at the Lundbeck Foundation. Prior to joining the Lundbeck Foundation in 2014, Lene Skole was CFO at Coloplast A/S where she was a member of the company’s executive management since joining in 2005. Lene Skole’s responsibilities included finance, IT, HR, communication, strategy and M&A. Before 2005, Lene Skole held various positions in the AP Moller-Maersk group most recently as CFO of Maersk Company Ltd., London from 2000-2005.
Lene Skole’s special qualifications for serving on Lundbeck’s Board of Directors include extensive knowledge and expertise within financing, strategy, business development and M&A as well as management experience from international companies including med-tech.
Lene Skole is deputy chairman of the Board of Directors of Ørsted A/S, Falck A/S, ALK-Abelló A/S, and TDC A/S, and member of the Board of Directors of Tryg A/S and Tryg Forsikring A/S.
Lars Holmqvist, MSc in Business Administration, was born on 4 September 1959 and is a Swedish citizen. He was nominated for election to Lundbeck’s Board of Directors at the 2015 annual general meeting. He is member of Lundbeck’s Audit Committee.
Lars Holmqvist is senior advisor within healthcare at Bain Capital. He previously served as vice president responsible for sales and marketing at Pharmacia. In addition he has held management positions in several pharma and med-tech companies including Boston Scientific Corporation, Medtronic, Applied Biosystems Group, DAKO and Agilent Technologies.
Lars Holmqvist’s special qualifications for serving on Lundbeck`s Board of Directors include his international management experience, his expertise in finance, and his sales and marketing experience from the global pharmaceutical, med-tech and life-science industry.
Lars Holmqvist is member of the Board of Directors of the Lundbeck Foundation, ALK-Abelló A/S, Tecan AG and Naka UK topco Ltd.
Jeremy M. Levin, BA Zoology, MA and DPhil in Molecular Biology and MB BChir Medicine and Surgery, was born on 9 September 1953 and is a British and US citizen. He was nominated for election to Lundbeck's board of Directors at the 2017 annual general meeting. Jeremy M. Levin has more than 25 years of experience in the global pharmaceuticals industry, leading companies and people to develop and commercialize medicines that address compelling medical needs worldwide.
Since 2014, he has been CEO and chairman of Ovid Therapeutics, a New York-based neurology company focused on rare and orphan diseases of the brain. Previously, Jeremy M. Levin served as President & CEO of Teva Pharmaceuticals and before becoming CEO of Teva, he was a member of the Executive Committee of Bristol-Myers Squibb where he was globally responsible for overall strategy, alliances and business development. Prior to that, he was Global Head of Strategic Alliances at Novartis, where he established and managed strategic collaborations with multiple companies and research institutions around the world.
Jeremy M. Levin’s special qualifications for serving on Lundbeck’s Board of Directors include a robust blend of clinical insight and experience, business development skills, corporate strategy and financial savvy. In addition he has substantial board experience.
Jeremy M. Levin is member of the Board of Directors of BioCon in India, ZappRx and on the Board and Executive Committee of BIO, the Biotechnology Innovation Organization in the USA.
Jeffrey Berkowitz, Juris Doctor and BA in Political Science, was born on 9 January 1966 and is a US citizen. He was nominated for election to Lundbeck's Board of Directors at the 2018 annual general meeting.
Jeffrey Berkowitz has recently served as an Executive Vice President of UnitedHealth Group (UNH), and CEO of their Optum International subsidiary since 2016. He served as Executive Vice President and President of Pharma & Global Market Access at Walgreens Boots Alliance, Inc. from 2015 and served first as Senior Vice President of Pharmaceutical Development and Market Access of Walgreen Co then as President of Walgreens Boots Alliance Development in the period 2010 – 2015. From 1998 to 2009, he held a variety of positions with increasing responsibility in market access, sales and marketing with Schering-Plough prior to its acquisition by Merck in 2009. Prior to joining Schering-Plough, Jeffrey Berkowitz was a health care attorney for the international law firm Proskauer, LLP in New York and Washington, D.C.
Jeffrey Berkowitz's special qualifications for serving on Lundbeck's Board of Directors include global experience with payers, pharmaceutical companies, specialty and retail pharmacies and wholesalers with responsibility for generic and branded procurement and inventory management, as well as pricing, reimbursement, specialty pharmacy and health care strategies. He and his team led the joint venture between Walgreens and Alliance Boots based in Bern, Switzerland and were key drivers of the merger surpassing aggressive synergy targets. Jeffrey Berkowitz has also been recognized in PharmaVoice magazine as one of the 100 Most Inspiring Leaders in the Life Sciences in 2009, 2010 and 2012 and serves on the Editorial Boards of Life Science Leader and Pharmaceutical Commerce magazines.
Jeffrey Berkowitz is independent director of Infinity Pharmaceuticals, Inc. and Esperion Therapeutics, Inc.
Henrik Andersen, Master of Law and graduate diploma in Trade and Finance, was born on 31 December 1967 and is a Danish citizen. He was nominated for election to Lundbeck's Board of Directors at the 2018 annual general meeting.
Henrik Andersen is Group President and CEO of Hempel A/S, a Danish based supplier of coatings with more than 5,500 employees across more than 80 countries. Prior to joining Hempel in 2016, Henrik Andersen was with ISS since 2000 where he held various positions. He was appointed to the Executive Board in ISS in 2011 first as CFO, later as Chief Operating Officer (COO) for EMEA and most recently Group COO. Henrik Andersen also spent seven years in the UK successfully growing ISS UK as CEO. Before joining ISS, Henrik Andersen was in the financial industry for 10 years.
Henrik Andersen's qualifications for serving on Lundbeck's Board of Directors include extensive experience with accounting, finance, capital markets, international business and strategic management of international companies.
Henrik Andersen is a member of the Board of Directors in Vestas A/S, member of the Board in Maj Invest Holding A/S (until April 2018) and member of The Investment Committee of Maj Invest Equity 4 K/S.
Jørn Mayntzhusen, BSc in Logistics and MBA, was born in 1966 and is a Danish citizen.
Jørn has been with Lundbeck since 2002, currently as a Senior Manager for Supply Optimisation and Launches of new products. Previously he has been responsible for Production Planning and Costing, as well as Head of Customer Supply.
Originally educated as a Banker in 1988, he has obtained a BSc in Logistics (HD(L)) at Copenhagen Business School in 1995 and a Master of Business Administration (MBA) from Edinburgh Business School in 2002.
Jørn started working with Handelsbanken from 1986-1990 followed by two years at Thule Air Base with Greenland Contractors from 1990-1992. In 1992, he started studying for his BSc and was employed as a Logistic Assistant with Braun Nordic from 1993-1997. For the next two years, Jørn worked as Business Management Advisor with Mellemfolkeligt Samvirke in Zimbabwe. Prior to working for Lundbeck, he was a Nordic Logistic Manager with Moulinex Krups from 1999-2002.
Rikke Kruse Andreasen, Laboratory Technician, was born in 1971 and is a Danish citizen.
Rikke has been with Lundbeck since 1995 as a Senior Laboratory Technician. In 2012, she was elected as a Union Representative for the laboratory technicians and as a Work Council member.
She is educated as a Laboratory Technician in 1991 at Laborantskolen Copenhagen, and in 2016 she completed a college education in Employment Law and Negotiation at Copenhagen Business School.
Rikke Kruse Andreasen started working with Statens Serum Institut from 1991-1995 as Section Laboratory Technician. Since working with Lundbeck, she has been in three different departments as a Senior Laboratory Technician.
Ludovic Tranholm Otterbein, MSc Molecular Biology and PhD, was born on 12 November 1973 and is a French citizen.
Ludovic has been with Lundbeck since 2011 and started as an external Lean Consultant. In his current role, Ludovic is the Director of Research Informatics and Compound management.
Ludovic completed his MSc in France in 1998 at Polytech Marseille, before moving to the United States of America to complete his PhD in Biophysics working on muscular diseases. Before joining Lundbeck, Ludovic was a Senior Consultant at Valcon Management Consulting where he helped clients within the pharmaceutical industry. Ludovic has also worked at AstraZeneca both in UK and Sweden from 2002-2010.